Intersect ENT (XENT) Misses Q1 EPS by 5c, Cuts FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intersect ENT (XENT) CEO Lisa Earnhardt is Stepping Down; Kieran Gallahue Appointed Executive Chairman
May 6, 2019 4:06 PM EDTIntersect ENT®, Inc. (Nasdaq: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that Lisa Earnhardt will be stepping down from her role as Chief Executive Officer on June 5, 2019 to accept another opportunity.
Kieran Gallahue, the companys Lead Director, has been appointed Executive Chairman of the Board of Directors, effective May 7, 2019, and Interim Chief Executive Officer, effective June 5, 2019. Ms. Earnhardt will remain a member of the Intersect ENT Board.
It has been an honor to lead Intersect ENT the past 11... More
